<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642482</url>
  </required_header>
  <id_info>
    <org_study_id>0711201127</org_study_id>
    <nct_id>NCT04642482</nct_id>
  </id_info>
  <brief_title>Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity</brief_title>
  <official_title>The Effect of Synbiotic on Intestinal Microbiota and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) on Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasanuddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasanuddin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background :&#xD;
&#xD;
      There is a plausible relationship between microbial gut and insulin resistance. Intervention&#xD;
      to prevent insulin resistance by modifying the microbial gut has been proposed but limited&#xD;
      studies demonstrates the expected impact. One of the possible way to manipulate the microbial&#xD;
      gut is the administration of synbiotic (prebiotic and probiotic).&#xD;
&#xD;
      Objective :&#xD;
&#xD;
      This study aim to address the impact of synbiotic administration to the microbial gut and&#xD;
      insulin resistance.&#xD;
&#xD;
      Brief Methodology :&#xD;
&#xD;
      A Quasi Experimental study with multiple arms is conducted to healthy participants. All&#xD;
      subjects will undergo a microbial gut taxonomic analysis using faecal sample and blood&#xD;
      examination to determine the insulin resistance status (using Homeostatic Model Assessment&#xD;
      for Insulin Resistance/HOMA-IR approach). Synbiotic will be given to intervention arm and&#xD;
      active comparator will use maltodextrin. Repeated measurement will be conducted after 8 weeks&#xD;
      and 12 weeks from the day of administration.&#xD;
&#xD;
      Hypothesis : A superiority trial hypothesis is applied, assuming that the synbiotic group&#xD;
      will demonstrates higher variety of microbial gut and lower HOMA-IR level&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Location :&#xD;
&#xD;
      This study will recruit the healthy participants from the university&#xD;
&#xD;
      Target Population:&#xD;
&#xD;
      Healthy Participants&#xD;
&#xD;
      General Study Design :&#xD;
&#xD;
      Quasi Experimental study with a comparator&#xD;
&#xD;
      Sample Size calculation :&#xD;
&#xD;
      Difference between two means of HOMA IR from pilot data (7) and standard deviation 2.9, with&#xD;
      5% Type I error, and 80% Power yielded a total of 16 participants for two arms&#xD;
&#xD;
      Management of Sample:&#xD;
&#xD;
        1. Faecal Sample handling&#xD;
&#xD;
             1. Patient should undergo 8 hours of fasting prior to faecal examination&#xD;
&#xD;
             2. DNA Extraction&#xD;
&#xD;
             3. Lysate preparation and centrifuge faecal sample&#xD;
&#xD;
             4. Mixing lysate with sample&#xD;
&#xD;
             5. Column wash&#xD;
&#xD;
             6. DNA elution&#xD;
&#xD;
             7. DNA storing&#xD;
&#xD;
             8. DNA sequencing and analysis&#xD;
&#xD;
             9. taxonomical analysis&#xD;
&#xD;
        2. Fasting blood glucose&#xD;
&#xD;
             1. Patient should undergo 8 hours of fasting prior to Fasting blood glucose&#xD;
&#xD;
             2. Blood is taken from cubital vein&#xD;
&#xD;
             3. Spectrometry is conducted based on the NADPH formation from the equation below&#xD;
&#xD;
           D-glucose+ATP -----&gt; Glucose-6-phospate+ADP Glucose-6-phospate+NAD ---- G-6-PDH ---&gt;&#xD;
           D-Gluconate-6 phospate+NADH+H&#xD;
&#xD;
        3. Insulin level&#xD;
&#xD;
             1. Centrifuge blood to obtain the serum&#xD;
&#xD;
             2. The monoclonal anti-insulin antibody is given to the serum&#xD;
&#xD;
             3. detection is based on the anti-insulin antibody and insulin complex formation&#xD;
&#xD;
        4. Homeostatic Model Assessment for Insulin Resistance/ HOMA-IR value is calculated from&#xD;
           glucose level multiply by insulin level and divided by 405.&#xD;
&#xD;
      Protection for adverse event&#xD;
&#xD;
        1. All subjects are given the consent regarding the potential harm of synbiotic&#xD;
           administration&#xD;
&#xD;
        2. All subjects will follow the protocol of reporting the any adverse event (most likely,&#xD;
           severe constipation)&#xD;
&#xD;
        3. All subjects will be treated accordingly and hospitalisation if needed.&#xD;
&#xD;
      Statistical Analysis&#xD;
&#xD;
        1. General Analysis : Intention To Treat (ITT)&#xD;
&#xD;
        2. Propensity Score Matching will be conducted prior to intervention&#xD;
&#xD;
        3. A repeated measure ANOVA will be performed, whereas Generalized Linear Mixed Model&#xD;
           treating the intervention as dummy variable will be performed if ANOVA assumptions can&#xD;
           not be fulfilled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 26, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multiple-arm study involves three different groups receiving synbiotic (probiotic + prebiotic) and placebo. Observation of intestinal microbiota and insulin resistance is observed in repeated measurement</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participants receive the synbiotic in the form of fine powder and taken orally and packed with similar packages. Care provider (Research assistants) distribute the unlabeled formulation to the participants. Outcome assessors (laboratory technician) will not be informed regarding the allocation. Investigators are blinded from allocation and will not be informed until the final analysis. Only the statistician will perform and aware of the allocation. A propensity matching score (PSM) is preferred to allocate the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Changes of HOMA IR value from baseline to 8 weeks</time_frame>
    <description>a value representing the insulin resistance yielded by multiplying the blood glucose value and insulin value, then divided by 405 (considering the unit of values are in mg/dL not mmol)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Abundance-based Coverage Estimator (ACE) Index of Faecal Sample</measure>
    <time_frame>Prior to intervention (Time 0), 8 weeks after Time 0, and 12 weeks after Time 0</time_frame>
    <description>This index defined as the sum of the probabilities of the observed species. The ACE method divides observed frequencies into abundant and rare groups. The abundant species are those with more than 10 individuals in the sample, and the rare species are those with fewer than 10 individuals</description>
  </other_outcome>
  <other_outcome>
    <measure>Shannon Index of Faecal Sample</measure>
    <time_frame>Prior to intervention (Time 0), 8 weeks after Time 0, and 12 weeks after Time 0</time_frame>
    <description>The Shannon diversity index to a value between 0 and 1. Lower values indicate more diversity of microbial gut while higher values indicate less diversity.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fine powder to be taken orally consists of&#xD;
Viable cell 1,0 x 10^9 Colony Forming Unit of :&#xD;
Lactobacillus plantarum 8,55 mg&#xD;
Streptococcus thermophilus 8,55 mg&#xD;
Bifidobacterium bifidum 2,55 mg&#xD;
Fructooligosaccharide 480 mg&#xD;
Additional components : isomalt, xylitol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A powder of 5 gram maltodextrin is given as active comparator, taken orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic (Rillus)</intervention_name>
    <description>Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.</description>
    <arm_group_label>Synbiotic</arm_group_label>
    <other_name>Rillus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age above 18 years old&#xD;
&#xD;
          2. Not receive antibiotic prescription within the last 6 months&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Taking medication that alters the blood sugar&#xD;
&#xD;
          2. Taking probiotic or synbiotic product (such as yogurt)&#xD;
&#xD;
          3. Participant who do not take the synbiotic intervention for more than 3 days&#xD;
             consecutively&#xD;
&#xD;
          4. incomplete follow up examination results&#xD;
&#xD;
          5. Develop adverse effect&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasrum Massi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andi Anggeraini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Muhammadiyah University</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <zip>90221</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Møller K, Svendsen KD, Jakobsen M, Pedersen BK. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010 Dec;104(12):1831-8. doi: 10.1017/S0007114510002874. Epub 2010 Sep 6.</citation>
    <PMID>20815975</PMID>
  </reference>
  <reference>
    <citation>Hagerty SL, Hutchison KE, Lowry CA, Bryan AD. An empirically derived method for measuring human gut microbiome alpha diversity: Demonstrated utility in predicting health-related outcomes among a human clinical sample. PLoS One. 2020 Mar 2;15(3):e0229204. doi: 10.1371/journal.pone.0229204. eCollection 2020.</citation>
    <PMID>32119675</PMID>
  </reference>
  <reference>
    <citation>Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev. 2013 Dec;14(12):950-9. doi: 10.1111/obr.12068. Epub 2013 Aug 16. Review.</citation>
    <PMID>23947604</PMID>
  </reference>
  <reference>
    <citation>Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab. 2012;61(2):160-74. doi: 10.1159/000342079. Epub 2012 Oct 2. Review.</citation>
    <PMID>23037511</PMID>
  </reference>
  <reference>
    <citation>Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007 Nov;50(11):2374-83. Epub 2007 Sep 6.</citation>
    <PMID>17823788</PMID>
  </reference>
  <reference>
    <citation>Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546-58. Review.</citation>
    <PMID>19442172</PMID>
  </reference>
  <reference>
    <citation>Chakraborti CK. New-found link between microbiota and obesity. World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):110-9. doi: 10.4291/wjgp.v6.i4.110.</citation>
    <PMID>26600968</PMID>
  </reference>
  <reference>
    <citation>Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506.</citation>
    <PMID>23985870</PMID>
  </reference>
  <reference>
    <citation>Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: How prebiotic can work? Br J Nutr. 2013 Jan;109 Suppl 2:S81-5. doi: 10.1017/S0007114512004047. Review.</citation>
    <PMID>23360884</PMID>
  </reference>
  <reference>
    <citation>Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci. 2004 Apr;49(4):579-89.</citation>
    <PMID>15185861</PMID>
  </reference>
  <reference>
    <citation>He C, Shan Y, Song W. Targeting gut microbiota as a possible therapy for diabetes. Nutr Res. 2015 May;35(5):361-7. doi: 10.1016/j.nutres.2015.03.002. Epub 2015 Mar 14. Review.</citation>
    <PMID>25818484</PMID>
  </reference>
  <reference>
    <citation>Kassaian N, Feizi A, Aminorroaya A, Jafari P, Ebrahimi MT, Amini M. The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial. Acta Diabetol. 2018 Oct;55(10):1019-1028. doi: 10.1007/s00592-018-1175-2. Epub 2018 Jun 22.</citation>
    <PMID>29931423</PMID>
  </reference>
  <reference>
    <citation>Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Res Rev. 2018 Jun;31(1):35-51. doi: 10.1017/S095442241700018X. Epub 2017 Oct 17. Review.</citation>
    <PMID>29037268</PMID>
  </reference>
  <reference>
    <citation>Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JB, Stroes ES, Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Feb;14(2):112-20. doi: 10.1111/j.1463-1326.2011.01483.x. Epub 2011 Nov 22. Review.</citation>
    <PMID>21812894</PMID>
  </reference>
  <reference>
    <citation>Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010 Feb 5;5(2):e9085. doi: 10.1371/journal.pone.0009085.</citation>
    <PMID>20140211</PMID>
  </reference>
  <reference>
    <citation>Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol. 2011 Mar;110(3):650-7. doi: 10.1111/j.1365-2672.2010.04922.x. Epub 2011 Feb 1.</citation>
    <PMID>21281408</PMID>
  </reference>
  <reference>
    <citation>Saad MJ, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiology (Bethesda). 2016 Jul;31(4):283-93. doi: 10.1152/physiol.00041.2015. Review.</citation>
    <PMID>27252163</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasanuddin University</investigator_affiliation>
    <investigator_full_name>Bumi Herman</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Intestinal Microbiota</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

